Xellia Pharmaceuticals is a specialty pharmaceutical company developing, manufacturing and commercializing anti-infective treatments against serious and often life-threatening bacterial and fungal infections. With over 115 years of experience, Xellia is a world-leading trusted supplier of several important established anti-infective drugs, comprising active pharmaceutical ingredients as well as injectable products. Continuing the Company’s evolution, Xellia is generating an innovative pipeline of value-added anti-infective medicines intended to enhance patient care, providing convenience and ease of use for healthcare professionals. Headquartered in Copenhagen, Denmark, Xellia has a global footprint with R&D, manufacturing and commercial operations across Europe, Asia, the Middle East and North America. Xellia is wholly owned by Novo Holdings A/S and employs a dedicated team of over 1,800 people.

Sales Markets

Middle East Region (e.g. UAE); Oceania; North America (USA, Canada); Africa; Central America (e.g. Mexico); East Asia (e.g. China, Japan, Korea); Europe - EU countries; Europe - non EU (e.g. UK, Russia, ex-CIS countries); South America (e.g. Brazil, Colombia); South Asia (e.g. India, Pakistan, Sri Lanka); South East Asia (e.g. Thailand, Philippines, Singapore)

Meet us at

CPhI Worldwide 2021

Fiera Milano, Milan, Italy

9-11 November 2021

Book a meeting
View Our Exhibitor Profile

Contact information

Address

Telephone

Website

View All Contact Info

Top Products

Daptomycin

Daptomycin

Xellia Pharmaceuticals ApS

Request Info
Vancomycin HCL vials

Vancomycin HCL vials

Xellia Pharmaceuticals ApS

Request Info
Polymyxin B vials

Polymyxin B vials

Xellia Pharmaceuticals ApS

Request Info
Amphotericin B

Amphotericin B

Xellia Pharmaceuticals ApS

Request Info

Our Resources

Categories affiliated with Xellia Pharmaceuticals ApS